Indivior (LON:INDV) Stock Price Up 11.9% – Still a Buy?

Posted by Joseph Casey on Oct 24th, 2024

Indivior PLC (LON:INDV – Get Free Report) shares were up 11.9% on Thursday . The stock traded as high as GBX 738 ($9.58) and last traded at GBX 731 ($9.49). Approximately 231,070 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 1,264,178 shares. The stock had previously closed at GBX 653.50 ($8.48).

Wall Street Analysts Forecast Growth

Separately, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a GBX 1,500 ($19.48) price target on shares of Indivior in a research note on Thursday, September 5th.

Read Our Latest Research Report on Indivior

Indivior Stock Performance

The stock has a market capitalization of £930.99 million, a price-to-earnings ratio of -816.88, a price-to-earnings-growth ratio of -5.57 and a beta of 0.19. The company has a debt-to-equity ratio of 2,790.00, a current ratio of 0.85 and a quick ratio of 1.52. The stock has a 50-day moving average of GBX 779.31 and a 200 day moving average of GBX 1,094.28.

Insider Transactions at Indivior

In other Indivior news, insider Jo Le Couilliard bought 1,490 shares of the company’s stock in a transaction on Friday, July 26th. The stock was bought at an average price of GBX 1,006 ($13.06) per share, for a total transaction of £14,989.40 ($19,461.70). 3.44% of the stock is owned by corporate insiders.

About Indivior

(Get Free Report)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.